Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: The ICP-bypass study;Magnitud y características del riesgo residual lipídico en pacientes con antecedentes de revascularización coronaria: estudio ICP-Bypass

Revista Espanola de Cardiologia

Volumn 64, Issue 10, 2011, Pages 862-868

  González Juanatey, José Ramón ^a   Cordero, Alberto ^b   Vitale, Gustavo C ^c   González Timón, Belén ^c   Mazón, Pilar ^a   Bertomeu, Vicente ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c Departamento Médico MSD España   (Spain)

Author keywords

High density lipoproteins; Low density lipoproteins; Residual lipid risk; Revascularization; Triglycerides

Indexed keywords

EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; AGE; AGED; ARTICLE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREVALENCE; RESIDUAL LIPID RISK; RISK; SMOKING;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RISK; SPAIN; TRIGLYCERIDES;

EID: 80052965525     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.05.022     Document Type: Article

References (40)

1. W.B. Kannel, T.R. Dawber, A. Kagan, N. Revotskie, and J. Stokes 3rd. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study Ann Intern Med 55 1961 33 50
2. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, and G. De Simone Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
3. S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, and F. Lanas Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952 (Pubitemid 39208455)
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
5. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
6. J.P. Després, I. Lemieux, G.R. Dagenais, B. Cantin, and B. Lamarche HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study Atherosclerosis 153 2000 263 272 (Pubitemid 32120325)
7. P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, and S.M. Grundy HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
8. G. Assmann, H. Schulte, P. Cullen, and U. Seedorf Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study Eur J Clin Invest 37 2007 925 932 (Pubitemid 350151189)
9. O. Bayturan, S. Kapadia, S.J. Nicholls, E.M. Tuzcu, M. Shao, and K. Uno Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol J Am Coll Cardiol 55 2010 2736 2742
10. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, and S. Bingham Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458 (Pubitemid 46184196)
11. O. Faergeman, I. Holme, R. Fayyad, S. Bhatia, S.M. Grundy, and J.J. Kastelein Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease Am J Cardiol 104 2009 459 463
12. B.J. Arsenault, J.S. Rana, E.S. Stroes, J.P. Despres, P.K. Shah, and J.J. Kastelein Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women J Am Coll Cardiol 55 2009 35 41
13. J. Ren, S.M. Grundy, J. Liu, W. Wang, M. Wang, and J. Sun Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS) Atherosclerosis 211 2010 327 332
14. J.C. Fruchart, F. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, and R. Ceska The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 K1 K34
15. H. Ghandehari, S. Kamal-Bahl, and N.D. Wong Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004 Am Heart J 156 2008 112 119
16. R.F. Otero, P. Mazón-Ramos, L. Grigorian-Shamagian, A. Nores-Lorenzo, L. Zugaza-Gurruchaga, and R. Seoane-Blanco Influencia de la diabetes en las características clínicas y el pronóstico de pacientes con cardiopatía isquémica crónica. Estudio CIBAR Rev Esp Cardiol 63 2010 1371 1376
17. J.R. González-Juanatey, E. Alegría-Ezquerra, J. Aznar-Costa, V. Bertomeu-Martínez, J. Franch-Nadal, and J.L. Palma-Gamiz Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas Rev Esp Cardiol 59 2006 801 806 (Pubitemid 44540835)
18. V. Bertomeu, A. Cordero, J. Quiles, P. Mazón, J. Aznar, and H. Bueno Control de los factores de riesgo y tratamiento de la cardiopatía isquémica: Registro TRECE Rev Esp Cardiol 62 2009 807 811
19. D.L. Bhatt, K.A. Eagle, E.M. Ohman, A.T. Hirsch, S. Goto, and E.M. Mahoney Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis JAMA 304 2010 1350 1357
20. P. Lazaro, N. Murga, D. Aguilar, and M.A. Hernández-Presa Inercia terapéutica en el manejo extrahospitalario de la dislipemia en pacientes con cardiopatía isquémica. Estudio Inercia Rev Esp Cardiol 63 2010 1428 1437
21. J.R. González-Juanatey, J. Millán, E. Alegría, C. Guijarro, J.V. Lozano, and G.C. Vitale Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España. Estudio DYSIS-España Rev Esp Cardiol 64 2011 286 294
22. J.J. Badimon, and B. Ibáñez Incremento de las HDL como arma terapéutica en la aterotrombosis Rev Esp Cardiol 63 2010 323 333
23. I. Lemieux, B. Lamarche, C. Couillard, A. Pascot, B. Cantin, and J. Bergeron Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study Arch Intern Med 161 2001 2685 2692 (Pubitemid 33134844)
24. A. Cordero, E. Andrés, B. Ordoñez, M. León, M. Laclaustra, and A. Grima Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men Am J Cardiol 104 2009 1393 1397
25. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, and J.C. Fruchart Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
26. L. Rydén, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, and M.J. de Boer Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136 (Pubitemid 46137814)
27. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
28. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1-266.
29. O. Vegazo, J.R. Banegas, F. Civeira, P.L. Serrano Aisa, F.J. Jiménez, and E. Luengo Prevalencia de dislipemia en las consultas ambulatorias del Sistema Nacional de Salud: Estudio HISPALIPID Med Clin (Barc) 127 2006 331 334 (Pubitemid 44580068)
30. R. Vidal-Pérez, F. Otero-Raviña, L. Grigorian-Shamagian, V. Parga-García, M.J. Eirís-Cambre, and C. De Frutos-de Marcos El sexo no condiciona diferencias en el pronóstico de pacientes diabéticos. Estudio Barbanza-Diabetes Rev Esp Cardiol 63 2010 170 180
31. C. Suárez, J. Castillo, E. Esmatjes, J. Sala, M. Cairols, and C. Montoto Complicaciones cardiovasculares a un año de seguimiento en pacientes con aterotrombosis. Registro REACH España Med Clin (Barc) 132 2009 537 544
32. M.J. Pérez-Vizcayno, R.A. Hernández-Antolin, F. Alfonso, C. Bañuelos de Lucas, J. Escaned, and P. Jiménez Evolución en los últimos 20 años en el perfil demográfico, epidemiológico y clínico, técnica y resultados de los procedimientos coronarios percutáneos Rev Esp Cardiol 60 2007 932 942
33. D.T. Ko, J.V. Tu, Z. Samadashvili, H. Guo, D.A. Alter, and W.J. Cantor Temporal trends in the use of percutaneous coronary intervention and coronary artery bypass surgery in New York State and Ontario Circulation 121 2010 2635 2644
34. K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyörä lä, and U. Keil Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
35. A.L. Avins, and J.M. Neuhaus Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 160 2000 1937 1944 (Pubitemid 30437578)
36. A. Cordero, M. León, E. Andrés, B. Ordoñez, M. Laclaustra, and A. Grima Gender differences in obesity related cardiovascular risk factors in Spain Prev Med 48 2009 134 139
37. J. Jeppesen, H.O. Hein, P. Suadicani, and F. Gyntelberg Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease Arch Intern Med 161 2001 361 366 (Pubitemid 32116551)
38. A. Cordero, M. Laclaustra, M. León, J.A. Casasnovas, A. Grima, and E. Luengo Comparison of serum lipid values in subjects with and without the metabolic syndrome Am J Cardiol 102 2008 424 428
39. P.M. Ridker, J. Genest, S.M. Boekholdt, P. Libby, A.M. Gotto, and B.G. Nordestgaard HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
40. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, and J.H. Stein Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524 (Pubitemid 351470037)